Close

Here we select some of the classical literature in the field of chimeric antigen receptor technology. It is hoped that these reviews and research articles will help you to understand CAR technology quickly and keep up with the cutting edge development of this area.

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Science translational medicine 6.224 (2014): 224ra25-224ra25.

Davila, Marco L., et al

The article discussed the efficacy and toxicity Management especially for cytokine release syndrome (CRS) management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. The paper shows results of treating advanced acute lymphoblastic leukemia with autologous T cells modified with a CD19-specific CAR containing the CD28 and CD3z signaling domains. An algorithm for identifying and managing patients with cytokine release syndrome is provided.

T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice

Molecular Therapy 23.10 (2015): 1600-1610.

VanSeggelen, Heather, et al.

A nagetive results in mice of CAR-T therapy that targ NKG2D ligands. This article concludes that while NKG2D ligands may be useful targets for immunotherapy, the pursuit of NKG2D-based CAR-T cell therapies should be undertaken with caution.

Toxicities of chimeric antigen receptor T cells: recognition and management

Blood 127, no. 26 (2016): 3321-3330.

Brudno, Jennifer N., and James N. Kochenderfer.

This review describes the toxicities maily of cytokine release syndrome (CRS) caused by CAR T cells and reviews the published approaches used to manage toxicities. The review present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Science translational medicine 6.224 (2014): 224ra25-224ra25.

Davila, Marco L., et al

The article discussed the efficacy and toxicity Management especially for cytokine release syndrome (CRS) management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. The paper shows results of treating advanced acute lymphoblastic leukemia with autologous T cells modified with a CD19-specific CAR containing the CD28 and CD3z signaling domains. An algorithm for identifying and managing patients with cytokine release syndrome is provided.

T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice

Molecular Therapy 23.10 (2015): 1600-1610.

VanSeggelen, Heather, et al.

A nagetive results in mice of CAR-T therapy that targ NKG2D ligands. This article concludes that while NKG2D ligands may be useful targets for immunotherapy, the pursuit of NKG2D-based CAR-T cell therapies should be undertaken with caution.

Toxicities of chimeric antigen receptor T cells: recognition and management

Blood 127, no. 26 (2016): 3321-3330.

Brudno, Jennifer N., and James N. Kochenderfer.

This review describes the toxicities maily of cytokine release syndrome (CRS) caused by CAR T cells and reviews the published approaches used to manage toxicities. The review present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Science translational medicine 6.224 (2014): 224ra25-224ra25.

Davila, Marco L., et al

The article discussed the efficacy and toxicity Management especially for cytokine release syndrome (CRS) management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. The paper shows results of treating advanced acute lymphoblastic leukemia with autologous T cells modified with a CD19-specific CAR containing the CD28 and CD3z signaling domains. An algorithm for identifying and managing patients with cytokine release syndrome is provided.

T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice

Molecular Therapy 23.10 (2015): 1600-1610.

VanSeggelen, Heather, et al.

A nagetive results in mice of CAR-T therapy that targ NKG2D ligands. This article concludes that while NKG2D ligands may be useful targets for immunotherapy, the pursuit of NKG2D-based CAR-T cell therapies should be undertaken with caution.

Toxicities of chimeric antigen receptor T cells: recognition and management

Blood 127, no. 26 (2016): 3321-3330.

Brudno, Jennifer N., and James N. Kochenderfer.

This review describes the toxicities maily of cytokine release syndrome (CRS) caused by CAR T cells and reviews the published approaches used to manage toxicities. The review present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Science translational medicine 6.224 (2014): 224ra25-224ra25.

Davila, Marco L., et al

The article discussed the efficacy and toxicity Management especially for cytokine release syndrome (CRS) management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. The paper shows results of treating advanced acute lymphoblastic leukemia with autologous T cells modified with a CD19-specific CAR containing the CD28 and CD3z signaling domains. An algorithm for identifying and managing patients with cytokine release syndrome is provided.

T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice

Molecular Therapy 23.10 (2015): 1600-1610.

VanSeggelen, Heather, et al.

A nagetive results in mice of CAR-T therapy that targ NKG2D ligands. This article concludes that while NKG2D ligands may be useful targets for immunotherapy, the pursuit of NKG2D-based CAR-T cell therapies should be undertaken with caution.

Toxicities of chimeric antigen receptor T cells: recognition and management

Blood 127, no. 26 (2016): 3321-3330.

Brudno, Jennifer N., and James N. Kochenderfer.

This review describes the toxicities maily of cytokine release syndrome (CRS) caused by CAR T cells and reviews the published approaches used to manage toxicities. The review present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.


Key Updates

Receive the latest news and insights to your inbox.